Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 544

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 544
---
| (6) | Ms. Johnson served as a director on the board of directors of Kintara prior to the consummation of the Kintara Merger and ceased serving on the board of directors in connection with the consummation of the Kintara Merger. |

| (7) | Ms. Favorito served as a director on the board of directors of Kintara prior to the consummation of the Kintara Merger and ceased serving on the board of directors in connection with the consummation of the Kintara Merger. |

| (8) | TuHURA did not make any stock option awards to its directors during the fiscal year ended December 31, 2024. |

337

On November 26, 2024, the TuHURA Board of Directors approved of a Non-Employee Director Compensation Program, effective beginning January 1, 2025. Each of TuHURA’s non-employee directors as of December 31, 2024 held the following outstanding options:

| Name(1)            |     | Shares Subject to Outstanding Options |
| James Manuso, Ph.D |     |                                27,106 |
| Alan List, M.D.    |     |                                27,106 |
| George Ng          |     |                                62,891 |

| (1) | Does not include the number of shares subject to outstanding options held by Mr. Toth, Ms. Johnson or Ms. Favorito, each of whom who ceased serving on the TuHURA Board of Directors in connection with the consummation of the Kintara Merger. |

338

TUHURA EQUITY COMPENSATION PLAN INFORMATION The following table provides certain information regarding TuHURA’s equity compensation plans in effect as of December 31, 2024:

| Plan category                                              |     | Number of         
 securities to be  
 issued upon       
 exercise of       
 outstanding       
 options, warrants 
 and rights(1)     
 (a)               |           |     | Weighted-average  
 exercise price of 
 outstanding       
 options,          
 warrants and      
 rights(2)         
 (b)               |      |     | Number of            
 securities           
 remaining            
 available for        
 future issuance      
 under equity         
 compensation         
 plans (excluding     
 securities reflected 
 in column (a))(3)    
 (c)                  |           |
|:-----------------------------------------------------------|:----|:------------------|----------:|:----|:------------------|-----:|:----